Back to top

Image: Bigstock

Luminex Corporation

Read MoreHide Full Article

Luminex’s assay revenues declined significantly in recent times. Per management, the departure of LabCorp has significantly impacted Luminex’s top-line performance. Additionally, the company’s MDx franchise revenues fell significantly. Contraction in gross and operating margins adds to the woes. On the brighter side, Luminex continues to gain from its flagship ARIES and VERIGENE platforms which have a strong customer base. Luminex’s System, Consumables and Royalty revenues improved significantly in recent times. These apart, the company’s efforts in controlling operating expenses are noteworthy. Management is optimistic about the recent EMD Millipore acquisition, which is expected to contribute significantly to the top line in 2019. Luminex outperformed its industry in a year's time.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Luminex Corporation (LMNX) - free report >>

Published in